Mazdutide is an investigational therapy currently in clinical trials, functioning as a dual GLP-1 and glucagon receptor agonist designed to reduce appetite while increasing energy expenditure
While Mounjaro (tirzepatide) is an excellent option for many, we believe in shedding light on alternative medications, ensuring accessibility to the most fitting treatment
Plaintiffs allege that these risks were not properly disclosed, leading to unexpected harm
Synergistic effect: The combination of the two can simultaneously enhance the skin's water retention ability and elasticity, achieving a dual effect of "hydration+wrinkle resistance"
You are interested in medical weight management but the weekly injection has kept you from starting You prefer a daily tablet over a weekly shot You have a BMI of 27 or higher with a weight-related health concern, or a BMI of 30 or higher You want a clinician-led plan with eligibility review, labs, and monitoring rather than a self-directed approach You want a US-compounded option and care about where your medication comes from Your PepScribe clinician makes the final call on eligibility based on your health history and goals
Some people wont need to stop tirzepatide at all